Document Detail

Neuroprotection for ischaemic stroke: Current status and challenges.
MedLine Citation:
PMID:  25196155     Owner:  NLM     Status:  Publisher    
Stroke is the third cause of death worldwide and the main cause of chronic, severe adult disability. We focus on acute ischaemic stroke, which accounts for approximately 80% of all strokes. The current therapy aims at restoring cerebral blood flow within a narrow time window in order to prevent damaging the "penumbra" which surrounds the infarct core. Intravenous thrombolysis remains the fundamental treatment worldwide, though not ideal for various restrictions and complications, limiting to 10% or less the percentage of patients treated within the appropriate time window. Neuroprotection is an alternative or adjunct approach to thrombolysis, targeting cerebral parenchyma in the acute ischaemic phase. Furthermore, neurorepair attempts to restore neuronal function in the after-stroke phase in those patients (treated or untreated) with significant impairment. In the past decades, the efficacy and safety of numerous candidate neuroprotective agents were showed in various animal stroke models. However, in clinical trials, promising pre-clinical studies have not been translated into positive outcomes. Our review will analyse the possible reasons for this failure and the new approaches and recommendations to overcome it, as well as novel strategies targeting additional events in ischaemia cascade. The combination of thrombolysis with pharmacological and non-pharmacological neuroprotective approaches has also been tested. Finally, the neurorepair strategy will be described with special emphasis on the role of cell-based therapies and ischaemic conditioning. Hopefully, the future therapy of ischaemic stroke will encompass a combination of neuroprotection (to stabilise penumbra), thrombolysis, antithrombotics (for secondary prevention) and neurorepair based on cell therapy plus rehabilitation.
Antonio Moretti; Federica Ferrari; Roberto F Villa
Related Documents :
9138835 - Diagnostic accuracy of dipyridamole technetium 99m-labeled sestamibi myocardial tomogra...
11433815 - Clinical analysis of myocardial perfusion and metabolism in patients with hypertrophic ...
12667565 - Electromechanical mapping for detecting myocardial viability and ischemia in patients w...
20458635 - Evaluation of (99)  (m)tcn-mpo as a new myocardial perfusion imaging agent in normal do...
7873475 - Amiodarone as a first-line drug in the treatment of atrial fibrillation: the protagonis...
16162795 - The left atrial appendage, a small, blind-ended structure: a review of its echocardiogr...
Publication Detail:
Type:  REVIEW     Date:  2014-9-4
Journal Detail:
Title:  Pharmacology & therapeutics     Volume:  -     ISSN:  1879-016X     ISO Abbreviation:  Pharmacol. Ther.     Publication Date:  2014 Sep 
Date Detail:
Created Date:  2014-9-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7905840     Medline TA:  Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014. Published by Elsevier Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Understanding Antihypertensive Medication Use after Living Kidney Donation through Linked National R...
Next Document:  Redox interactions between Cr(VI) and Fe(II) in bioreduced biotite and chlorite.